Source: International Congress 2018 – Pulmonary hypertension: therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Kan (Taipei, Taiwan), . Chen (Taipei, Taiwan), C. Hsu (Taipei, Taiwan), Y. Lin (Taipei, Taiwan). Inhaled liposomal iloprost shows high drug encapsulation, extended release profile and potentials of improving patient compliance. 3038

Member's Comments

No comment yet.

Related content which might interest you: Inhaled liposomal treprostinil (L606) shows extended release in healthy volunteer, as well as prolongs pharmacological effect in hypoxia-induced rat. Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology Source: Eur Respir J 2001; 17: 157-158 Year: 2001 Systemic bioavailability of inhaled corticosteroids: appropriate and comparable methodology Source: Eur Respir J 2001; 18: 246 Year: 2001 Inhaled liposomal iloprost extend detectable plasma level and prolong reduction of hypoxia-induced pulmonary hypertension in rat Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Prolonged activity where it matters - the reversible esterfication of budesonide improves its topical anti-inflammatory efficacy and selectivity in the airways Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 Inhaled solid lipid nanoparticles as a new tool for drug delivery in the lung Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006 Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007 Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001 A multicompartmemt lung model predicts pulmonary pharmacokinetics of inhaled liposomal treprostinil (L606) in healthy volunteer Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Stability and achievement of asthma control with higher doses of inhaled conticosteroids regular treatment Source: Annual Congress 2011 - Asthma management and response Year: 2011 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy Source: Eur Respir J 2007; 30: Suppl. 51, 713s Year: 2007 Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy Source: Eur Respir Rev 2008; 17: 41-42 Year: 2008 Efficacy of low dose theophylline in patient with bronchial asthma - anti-inflammatory effect Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003 Reduction in nebulisation time of aqueous drug solutions by the eFlow rapid in comparison to a jet nebuliser to improve patient convenience and compliance Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005 The impact of a high fine particle fraction inhaled long acting ß2 agonist (Formoterol) on airway function in asthma: evaluation with oxygen enhanced MRI and multiple breath washout. Source: International Congress 2017 – Imaging markers for COPD and asthma Year: 2017